Topic: adult stem cells

Magenta gains $50M Series B, Novartis candidate and new partnership

It was only six months ago, in a unique matchup, that venture capital firms Atlas and Third Rock came together in a $48.5 million Series A to create and launch Magenta Therapeutics; now, the upstart has added more cash, a new drug and a key collab for its Series B as it looks to waste no time boosting its clinical work.